News|Articles|December 1, 2025
Siemens Healthineers Unveils Expanded Capabilities of Contrast-Enhanced Mammography System at RSNA
Author(s)Jeff Hall
The addition of ClearCEM to Mammomat B.brilliant devices reportedly enhances differentiation of suspicious areas in image reconstruction and facilitates improved accuracy with tomosynthesis-guided biopsies.
Advertisement
For contrast-enhanced mammography (CEM), utilizing the new ClearCEM technique — recently introduced at the
Advanced algorithms for the
When CEM findings lead to a subsequent biopsy, Siemens Healthineers said ClearCEM provides a high-depth resolution localizer image that can facilitate accuracy within 1 mm for targeting of tomosynthesis-guided biopsy procedures.
“The image quality with ClearCEM is exceptional, even in dense breast tissue. ClearCEM provides a remarkably uniform background, which significantly improves the visibility of enhancing lesions,” noted Dianne Georgian-Smith, M.D., a radiologist at Envision Healthcare in Nashville.
Advertisement
Related to this article
In a recent interview, Phillip Koo, MD, discussed emerging trends with AI, theranostics and empowered patients, and how these developments may lead to challenges and potential opportunities for radiologists and nuclear medicine physicians.
How will generative AI software be evaluated by the FDA in the future? What’s next for point-of-care ultrasound? What steps have been successful in facilitating adoption of AI applications across enterprise systems? Leaders in radiology and health care will be discussing these topics and more at the upcoming HLTH USA conference.
In the third of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss recent developments with autonomous AI in breast imaging and share their perspective on the overall potential of AI to help mitigate the radiologist shortage.
In a recent interview, Amir Iravani, MD, FRACP, discussed the radiotherapeutic agent 177Lu-edotreotide and new dosimetry data from the COMPETE trial that was recently presented at the ASTRO conference.
In the second of a three-part podcast episode, Wendie Berg, MD, PhD, FACR, FSBI, Manisha Bahl, MD, and Amy Patel, MD discuss how to handle disagreements with adjunctive AI in breast imaging, whether to include AI assessments in PACS, and whether patients should pay for the use of adjunctive AI.
For patients with localized prostate cancer, stereotactic body radiotherapy (SBRT) offered comparable freedom from biochemical/clinical failure at eight years and nearly 40 percent lower urinary incontinence in comparison to radical prostatectomy, according to research presented at the ASTRO conference.
In a new podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.
The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
Can MRI-Based AI Have an Impact in Reducing Unnecessary Prostate Biopsies?
3
FDA Clears AI-Enabled FFR-IQ Software for Estimating Fractional Flow Reserve from CCTA
4
Can the Kaiser Score with Breast MRI Improve Clarity for BI-RADS 0 and 4 Assessments on Mammography and Ultrasound?
5